Royalty Report: Drugs, Biotechnology, Cancer – Collection: 7497

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Biotechnology
  • Cancer
  • Wound Care
  • Therapeutic
  • Diagnostic
  • Medical
  • Supply
  • Test/Monitoring
  • Ophthalmological
  • Disease
  • Dental
  • Veterinary
  • Orthopedic
  • Pharmaceuticals
  • Antibody
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7497

License Grant
Licensor grants a nonexclusive, worldwide license to Licensee to make, have made, use and sell TGF- beta 2 and TGF-beta Heterodimer as part of a Licensee's Licensed Product (i) for systemic administration for the treatment or prophylaxis of autoimmune diseases or conditions ('Autoimmune Use'), osteoporosis ('Osteoporosis Use'), and soft tissue wound healing (other than the healing of soft tissue wounds caused principally by vascular ischemia or reperfusion injury) ('Wound Healing Uses') and for bone marrow and stem cell protection allowing high dose cytotoxic chemotherapy in cancer patients ('Chemotherapy Use'), and (ii) for systemic or local or regional administration for direct anti-proliferative effects on solid cancerous tumors and lymphomas ('Cancer Use') and for the treatment or prophylaxis of prostatic hypertrophy ('Prostate Use') (collectively these six Uses are referred to as 'Systemic Uses').
Licensee may grant one sublicense under this license only to one other party in any country for each Systemic Use at any one time.
License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence hereto, and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.

IPSCIO Record ID: 4450

License Grant
Licensor grants to Licensee an exclusive, worldwide license to make, have made, use and sell TGF-beta 2 and a nonexclusive, worldwide license to make, have made, use and sell TGF-beta Heterodimer, in either case as part of a Licensee's Licensed Product solely for the local treatment or prophylaxis of wounds, diseases or conditions primarily affecting the dermis, including, without limitation, chronic and acute wounds and burns ('Local Dermal Uses').

Licensee may grant one sublicense under this license only to one other party in any country for all indications of Local Dermal Use at any one time.

License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.

IPSCIO Record ID: 4449

License Grant
Licensor grants a nonexclusive, worldwide license to Licensee to make, have made, use and sell TGF-beta 2 and TGF-beta Heterodimer as part of a Licensee's Licensed Product solely for the treatment or prophylaxis of diseases and conditions of the eye ('Ophthalmological Uses').

Licensee may grant sublicenses under this license only to one other party in any country for each indication of an Ophthalmological Use at any one time.

License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence set forth hereto, and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.

IPSCIO Record ID: 4448

License Grant
Licensor grants a nonexclusive, worldwide license to Licensee to make, have made, use and sell TGF-beta Receptor as a part of a Licensee's Licensed Product solely for the treatment or prophylaxis of disease or solely to be used as part of a process used to identify compounds useful in the treatment or prophylaxis of disease. Licensee may grant one sublicense under this license only to one other party in any country for each indication or research application at any one time.
License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence as detailed in the agreement, and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

'Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

Field of Use
Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis. Periodontal disease and gingivitis occur when bacteria from plaque colonize on the gingival (gum) tissue, either above or below the gum line.

IPSCIO Record ID: 7498

License Grant
Licensor grants nonexclusive, worldwide, license to Licensee to make, have made, use and sell TGF-beta 2 and TGF-beta Heterodimer as part of a Licensee's Licensed Product solely for research, diagnostic reagents or veterinary uses ('Research, Diagnostic and Veterinary Uses').

Licensee may grant sublicenses under this license only to one other party in any country for each indication of a Research, Diagnostic and Veterinary Use at any one time.

License Property
Licensor has certain patent rights relating to TGF-beta and the TGF-beta receptor.

'TGF-beta' shall mean any protein which is a member of that class of proteins designated as TGF-beta or transforming growth factor-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions and/or additions of one or more amino acids to the structure of a TGF-beta (but excluding TGF-beta 2 or TGF-beta Heterodimer), provided that such derivative protein is more similar in structure to the TGF-beta from which it was derived than it is to TGF-beta 2 or TGF-beta Heterodimer and provided that the primary biological activity of the derivative protein is substantially the same as the primary biological activity of the TGF- beta from which it was derived.

'TGF-beta 2' shall mean a protein comprising the amino acid sequence set forth and/or (i) fragments, fusions or precursors of the foregoing, and/or (ii) any derivative protein which results from making deletions, substitutions or additions of one or more amino acids to the structure.

'TGF-beta Heterodimer' shall mean the TGF-beta 2.3 heterodimer.

'TGF-beta Receptor' shall mean a protein, including a lipoprotein or glycoprotein, that interacts with TGF-beta so as to modulate its activity and that binds TGF-beta with high affinity (Kd 1000nM or less). Such TGF-beta Receptor may be cell associated or in soluble form.

Product' shall mean any pharmaceutical formulation or product or method or system which contains the protein TGF-beta 2, TGF-beta Heterodimer or TGF-beta Receptor.

'Phase I/II Clinical Trial' shall mean a controlled study in humans of the safety and efficacy of a Licensed Product for a particular indication or indications in subjects having the disease or condition under investigation.

Field of Use
Therapeutic Use shall mean any use of a Licensed Product or Licensed Method in vivo, in humans and animals, for the prevention, cure, amelioration or modification of any disease, symptom, syndrome, or other medical condition.

IPSCIO Record ID: 26594

License Grant
The Licensor hereby grants to the Licensee an exclusive license under the Licensed Rights to under the Licensed Property.  The Licensee has a unique opportunity to accelerate our development by utilizing intellectual property, drug leads, new research technologies, technical know-how and original scientific concepts derived from 25 years of research achievements relevant to cancer by licensed patent applications and patents.
License Property
CCF Technology shall mean all CCF’s unpatented inventions, know-how, trade secrets, analysis, discoveries, techniques, methods, clinical and other data, and other intellectual property relating to the research of Doctor or arising out of or in direct connection with work of Doctor in the field of regulating cell death (I) curing cancer treatment side effects by differential modulation cell death / survival mechanisms uniquely deregulated in cancer cells; (ii) selective sensitization of cancer cells to treatment by using the same approach; (iii) using anti-apoptotic proteins secreted by microbial parasites to cure tissue damage associated with cancer treatment, inflammation and other pathologies (stroke, heart attack).

Provisional Patent Application 60/526,538 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,666 – Methods of Identifying of Modulators of Apoptosis From Parasites and Uses Thereof U.S. Provisional Patent Application 60/526,496 – Methods of Inhibiting Apoptosis Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,667 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,460 – Methods of Protecting Against Radiation Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,461 – Methods of Protecting Against Radiation Using Flagellin U.S. Provisional Patent Application 60/571,149 – Small Molecules Inhibitors of MRP1 and Other Multi drug Transporters U.S. Provisional Patent Application 60/589,637 – Activation of p53 and Inhibition of NF-kB for cancer treatment.

Field of Use
Licensed Field shall mean shall mean the practice, production, manufacture, sale and use of the Licensed Rights for the discovery, development and commercialization of methods, techniques, devices, systems, animals and therapeutics in the field of regulating cell death

CBLC100 series small molecules that restore the activity of p53 tumor suppressor in cancers, including renal cell carcinomas, sarcomas, prostate cancers and other types of malignancies; curaxines and derivatives thereof are representative examples of this category;
CBLB101 series substances of biological nature (i.e., cytokine, chemokines and other secreted molecules) and their bioactive derivatives produced by tumor cells and capable of modulating cell survival; TGFß2 and derivatives thereof and derivatives thereof are representative examples of this category;
CBLB501 series natural factors produced by extracellular parasites and symbiont of humans and other mammalian species and their bioactive derivatives capable of modulating cell survival mechanisms of host cells; flagellin of Salmonella typhimurium and derivatives thereof are representative examples of this category;
CBLC500 series small molecules modulating tumor and normal cell sensitivity to cytotoxic chemicals by altering activity and substrate specificity of multi drug transporters; inhibitors of MRP1 and derivatives thereof are representative examples of this category.

IPSCIO Record ID: 372627

License Grant
By the 2003 agreement, Licensor granted an exclusive worldwide sublicense for the Licensed Technology in the Field of Use and the Field of Extended Use.  This amended and restated agreement is to continue the Exclusive Sublicense with the amendments.

Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.

For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.

License Property
Licensed Products means any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins and in combination with a synthetic or natural matrix, or any part thereof i.e., any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins without a matrix, or a synthetic or natural matrix alone, that is covered by the Licensed Patents; is developed through the use of a process that is covered by the Licensed Patents or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Patents.

Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.

Field of Use
GEM 21S was approved by the U.S. Food and Drug Administration the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease.

GEM 21S® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.

GEM 21S® growth-factor enhanced matrix combines a bioactive protein – highly purified rhPDGF-BB – with an osteoconductive matrix, ß-TCP.

GEM 21S® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranio• maxillofacial osseous defects.

The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.

IPSCIO Record ID: 7601

License Grant
University grants to Licensee and its Affiliates under the Licensed Patents an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory.
License Property
Invention Disclosures

10031C –Methods and Uses to Alter Neuronal Stem Cell Fate

10037C — Use of soluble Fas (CD95) in cyanoacrylate to promote wound healing and as a wound sealant (no patents filed under this number)

10038C — Promotion of diabetic wound healing by incorporation of insulin in a cyanoacrylate wound sealant (no patents filed under this number)

10039C — Use of soluble FasL in cyanoacrylate to promote wound healing and as a wound sealant (no patents filed under this number)

10040C –Wound healing promotion by delivery of colloidal silver in a cyanoacrylate wound sealant

2002.012C –Use of Low Frequency Microwave for Repair of Central Nervous System Injury Including Stroke, Trauma, Alzheimers, Parkinson's Disease, Multiple Sclerosis

2002.013C — Use of Low Frequency Microwaves to Alter Plasma Membrane Potential in Cells in Diseases (no patents filed under this number)

2002.014C –Use of Low Frequency/Intensity Microwaves in Combination with Metallic Particles to Enhance the Effect of Microwaves on Electron Transport and Mitochondrial Function (no patents filed under this number)

2002.015C –Use of 2-deoxyglucose to Promote the Effectiveness of Low Frequency/Intensity Microwaves to Alter Mitochondrial Function (no patents filed under this number)

2002.016C –Use of Low Frequency Microwaves to Alter Electron Transport in Mitochondria of Wounds (no patents filed under this number)

2002.017C — Use of Low Intensity Microwaves to Modulate Expression and Transport of Costimulatory Molecules (no patents filed under this number)

2002.018C –Use of Low Frequency/Intensity Microwaves as a Method for the Detection of Breast Cancer Cells (no patents filed under this number)

2002.019C –Use of Low Intensity Microwaves to Treat Type I and Type II Diabetic Neuropathies, Nephropathies, Pathologies of the Eye, Muscle Wasting, and Wound Healing (no patents filed under this number)

2002.020C –Use of Low Frequency Microwaves to Treat Cancers in Concert with Immunological Therapeutics (no patents filed under this number)

2002.021C –Use of Low Frequency Microwaves as a Method of Augmenting Traditional Chemotherapeutic Techniques and/or Traditional Radiation Therapy (no patents filed under this number)

2002.022C –Methods and Uses of Radio Protection Using Small Acidic Spore Protein and Human and Animal Analogs of Small Acidic Spore Protein (no patents filed under this number)

2002.023C — Method of Promoting, Preventing, Sustaining, or Shortening Neural Synapse by Manipulation of Mitochondrial, Liposomal, or Plasma Membrane Uncoupled (no patents filed under this number)

2002.030C –Methods and Products to Lower, Increase, or Remove Cell Surface Costimulatory Molecules by Altering Levels of Intracellular Reactive Oxygen Intermediates (no active patents)

2002.031C –Use of Inhibitors or Promoters of 2, 4 dienoyi-CoA-reductase to Promote or Prevent Reactive Oxygen Production

2002.032C –Use of Inhibitors or Promoters of 2,4 denoyi-CoA-isomerase to Promote or Prevent Reactive Oxygen Production (no patents filed under this number)

2002.033C — Use of Probiotic Delivery of Self Antigens for Immunological therapy in Autoimmune Diseases/Use of Various Strains of Probiotics to Determine Cytokine Bias (no patents filed under this number)

2002.034C — Use of Oral Administration ofT Cell Receptor Peptides Expressed in Probiotic Delivery System to Induce Therapeutic Immune Responses as Indicated (no patents filed under this number)

2002.035C –Use of Ligands for B7.1, B7.2, CD28, or CTLA4 in Cyanoacrylates to Promote Wound Healing (no patents filed under this number)

2002.036C — Use of Microwaves and Cyanoacrylate to Promote Wound Healing (no patents filed under this number)

2002.081C –Methods and Uses to Alter Neuronal Stem Cell Fate by Manipulation of Uncoupling Protein(s)

2002.119C –A Means of Preserving Organs, Tissue, and Stem Cells for Transplant, and for Improving the Success of Transplantation (no patents filed under this number)

CU1008C –Methods for Lowering Costimulatory Molecule Expression on Embryonic Stem Cells through Modulations of Oxidant Levels in the Cell with or without TCR Peptide or Other Peptide Vaccination (no patents filed under this number)

CU1014C –Method to Determine Rates of Cellular Division, Apoptosis, Oncosis or Growth Arrest through Use of Flow Cytometry (no patents filed under this number)

CU1047C –The use of saturated and polyunsaturated fatty acids to promote the effectiveness of gamma interferon as an immunogenic agent (no patents filed under this number)

CU1048C –A Diagnostic Screen of Peripheral Blood as an Indicator of Metabolic Dysfunction and Consequent Altered Immunity Disease (no patents filed under this number)

CU1049C — Use of polyphosphorylated nucleotides to change metabolic base states in cells (no patents filed under this number)

CU1050C –Methods and uses to induce or inhibit translocation of uncoupling proteins to and from cellular sites including plasma membrane organelles (no patents filed under this number)

CU1063C –Use of Fas Engagement and Selective Fatty Acids to Promote or Prevent Cell Viability Through Induction of Active Uncoupling Proteins Activity (no patents filed under this number)

CU1065C — Microinjection of Mitochondria Into Stem Cells, Growing Cells, or Dysfunctional Cells as a Therapeutic Manipulation in Diseases (no patents filed under this number)

CU1081C –Biochemical Process for the Separation of Toxic Substances, Including Heavy Metals Contained in Circuit Boards (no active patents)

CU1098C –A Therapeutic Approach to Pathogenesis of Down Syndrome (no patents filed under this number)

CU1099C –Blood Test for Early Detection of Down Syndrome (no patents filed under this number)

CU1105C — Micro/Nano Devices and Nanoparticles and Implants for Detecting and Altering Cellular and Tissue Metabolism (no patents filed under this number)

CU1125C –Methods and uses to protect or destroy nuclear DNA by manipulations of a newly discovered nuclear membrane uncoupling protein (UCP) or uncoupling-like protein/molecule (no patents filed under this number)

CU1128C –NUCLEI Methods and Uses to Protect or Destroy Nuclear DNA by Manipulations of a Newly Discovered Nuclear Membrane Uncoupling Protein (UCP) or Uncoupling-Like Protein Molecule (no patents filed under this number)

CU1138C — Novel Therapies for Tissue Repair, Remodeling, Reconstruction and Regeneration

CU1244C –Methods and Uses to Kill Tumor Cells In Vivo Using a Toxin Derived from the Black Widow Spider, Latrotoxin (no patents filed under this number)

CU1245C –The Use of Genistein to Supplement the Activity of Chemotherapeutic and Metabolic Modifying Agents (no patents filed under this number)

CU1246C –Use of Myxococcus Xanthus to Eliminate the Environmental Toxicity of Methane Production by Methanobacteria (no patents filed under this number)

CU1248C –Computer Software for Improved Flow Cytometric Data Analysis (no active patents)

CU1249C — Cybenetic Biovitiation (no patents filed under this number) CU1344C –Array for Metabolic Analysis (no active patents)

CU1518C — Myxococcus xanthus derived oncolytic agent (no patents filed under this number)

CU1696H –Induction of apoptosis in tumor cells (no patents filed under this number)

CU1715C –Metabolic Modifications in Plants as a Mechanism for Increasing Plant derived Ethanol or Oil for Fuel Production

CU1968C –Inhibition of Fatty Acid Oxidation (FAO) to potentiate drug sensitivity in breast cancer

CU2407H –Systems and Methods for Treating Human Inflammatory and Proliferative Diseases and Wounds, with a Combination of Chloroquine and a Glycolytic Inhibitor

CU2421H –Proteins for Use in Diagnosing and Treating Infection and Disease

IPSCIO Record ID: 160766

License Grant
Licensor hereby grants to Licensee a series of options to acquire exclusive United States and worldwide licenses, as set forth below, to make or have made, use, sell and sublicense Licensed Products under the Technology Rights for Orthopaedic Applications of the type described. Each such license shall run for the lives of all Patents and other patents owned by or licensed to Licensor, and related to any Licensed Product, which are appropriate for the territory licensed.
License Property
Licensed Products means devices or materials including but not limited to TP508 and related peptides, all products using any of such materials, Licensor Technology or any of the Technology Rights, and all other products which, in the course of their manufacture, use, or sale would, in the absence of this license, infringe one or more claims of any of the Patent Rights which have not been finally adjudicated to be invalid by a court of competent jurisdiction.

Licensor Technology means the core technologies related to the Patents, including the TP508 Peptide.

Licensor Product means TP508 or any related peptides, or any other materials or products manufactured by or for Licensor and sold to Licensee for research, treatment of patients or resale.

Patents means U.S. patents Number 5,352,664 and 5,500,412, all related foreign patents, including patents issued in Europe, Canada and Japan, and any divisional, continuation, and continuation-in-part applications and patents based thereon, any reissues or extensions thereof, and any corresponding or additional United States and foreign patent applications.

Field of Use
This agreement pertains to the medical industry relating to Orthopaedic Applications that shall include, and be limited to, the use of the Technology Rights in connection with Treatment of fractures, osteoarthritis or osteoporosis, treatment of damage to meniscus, ligament, cartilage or tendon, preparation or application of segmental bone filling, coating or preparation of bone or joint implants, and spinal fusion (bone related).

IPSCIO Record ID: 227278

License Grant
University hereby grants to Licensee in the territory and in the field an exclusive commercial license under University patent rights, to make and have made, to use and have used, to sell and have sold the licensed products, and to practice the licensed processes, for the life of the university patent rights. Such licenses shall include the right to grant sublicenses.
License Property
Universitys rights in the United States Patents listed below, and the inventions described and claimed therein
U.S.P.N. 5,019,559 – Wound healing using PDGF and IGF-II
U.S.P.N. 4,861,757 – Wound healing and bone regeneration using PDGF and IGF-I
U .S.P.N. 5,124,316 – Method for periodontal regeneration
U.S.P.N. 4,874,746 – Wound healing composition of TGF-alpha and PDGF
U .S.P .N. 4,983,581 – Wound healing composition of IGF-I and TGF-.beta.
U.S.P.N. 5,256,644 – Wound healing using IGF-II and TGF
U.S.P,N. 5,034,375 – Process of wound healing using PDGF and EGF
U.S.P.N. 5,035,887 – Wound healing composition of IL-1 and PDGF or IGF-1
U.S.P.N. 5,516,699 – Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity

rhPDGF is a bio-active protein that is a key mediator of wound healing and tissue regeneration.

Field of Use
rhPDGF is a key stimulator of the body's natural wound healing process. It has a well-established mechanism of action that leads to stimulation of certain cell types, including those important to bone, cartilage, tendon and ligament healing.

IPSCIO Record ID: 28726

License Grant
Licensor hereby grants Licensee an exclusive license, with the right to grant sub-licenses, under the OSI Patents and OSI Know-How, the right to manufacture, use and sell the Products for the Licensed Indications within the Territory.
License Property
'Compound' shall mean transforming growth factor Betas ('TGF-Betas') as described in the OSI Patents.

'OSI Patents' shall mean all of Licensor's right, title and interest in and to the patents relating to TGF-Betas set out in Schedule 1 to the Agreement and corresponding foreign patents or applications therefore, together with any patents issuing on the said applications, or any addition, continuation, continuation-in-part, division, reissue, renewal or extension based thereon (including any supplementary protection certificate based on the said patents).

'OSI Know-How' shall mean all information and material, technical data and other know-how invented, developed or acquired by, or under the control of any party hereto and which directly relates to the Compound or the Product, or to the development, manufacture or use of the same, including but not limited to chemical data, toxicological and other pre-clinical data, product forms and formulations, control assays and specifications and methods of preparation and stability data, all such data belonging to one party constituting that party's confidential information.

'Products' shall mean pharmaceutical preparations containing the Compound designed for administration to human beings which fall within the scope of the claims of the OSI Patents.

'Licensed Indications' shall mean (1) oral mucositis arising from the use of chemotherapy or radiation therapy in the treatment or prevention of cancer, and (2) topical or local (as opposed to systemic) application of the Products including, but not limited to, the healing of soft tissue wounds however caused, and the treatment of ophthalmic conditions and psoriasis, but excluding topical application in the gastrointestinal tract in the treatment or prevention of cancer or the management of side effects or adverse reactions arising from the use in the treatment or prevention of cancer of chemotherapy or radiation therapy; and also (3) all other indications deemed to be included in the Licensed.

IPSCIO Record ID: 256279

License Grant
The German Licensor grants an exclusive. even as to Licensor, right and license under the Licensed Technology, to make, have made, use, offer for sale, sell, and import Collaboration Products in the Territory for any use in humans.

Licensor grants a worldwide, co-exclusive, with Licensor, right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology to make, have made, use, offer for sale, sell, and import any product that is not a BiTE Product for any use in humans.

License Property
Collaboration Product means any composition or formulation containing a BiTE Molecule binding to a Collaboration Target.

BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.

Target means a cell-surface antigen.  The list of proprietary targets is epha2, alpha – V, and, beta-3.

BiTE(R) molecules are part of a novel class of antibody derivatives that may have the potential to selectively direct and activate the human immune system to act against cancer cells. This action is believed to occur as a result of the molecule's stimulation of T cells to target and destroy cancer cells that express a specific antigen.

Field of Use
This product collaboration is useful for the development of antibody-based pharmaceutical products.

BiTE molecule targeting CD19 is for the potential treatment of certain lymphomas.

IPSCIO Record ID: 6107

License Grant
Licensor hereby grants to Licensee a non-revocable, royalty-bearing exclusive right within the Territory to the Patent Rights in the Field, including the right to sublicense to third parties within the Field, provided that any third party sublicensee shall be subject to all of Licensee's obligations.
License Property
The Parties entered into a joint patent ownership and License Agreement dated as of August 16, 2004, which was later amended and restated as of May 23, 2006, for consideration the sufficiency of which was acknowledged in each Agreement, pursuant to which Licensor granted Licensee a 50% ownership interest in certain patents and patents applications listed in the Joint Ownership Agreement, as well as certain future patent rights, and the parties acknowledge that Licensee would have exclusive rights within a defined filed, while Licensor would have exclusive rights outside that field. Licensee and Licensor now wish to enter a new Agreement superseding the Joint Ownership Agreement so as to specify those future patents and patent applications that are to be subject to joint ownership and so as to restate the Licenses granted in the Joint Ownership Agreement. The Parties acknowledge that the jointly owned and cross-Licensed rights are vital to the parties’ respective plans for development and commercialization and wish to further clarify the parties’ respective rights and provide for continued access to the necessary rights in the event of insolvency.

Jointly Owned Patent Applications shall mean the pending Foreign Patent Applications listed below, including any foreign national patent applications which claim priority to the Foreign Patent Applications and any Future Patent Applications, including any continuations, divisionals, re-exams, reissues and continuations-in-part and any other forms of related applications, that claim domestic or international priority to any of the Issued United States or foreign patents, or pending international or foreign patent applications, specifically listed by patent or application number herein.

(a) Issued US Patents

(i) U.S. 6,268,178 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides; and

(ii) U.S. 6,642,026 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.

(iii) U.S. 6,773,899 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(iv) U.S. 6,794,162, entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(b) Foreign Patent Applications

(i) International Patent Applications. All foreign patent applications related to the above-referenced U.S. patents and applications and claiming priority to the following international patent applications under the Patent Cooperation Treaty (PCT)

A. International Patent Application No. PCT/US00/40020, published as International Publication No. WO 00/71731 A2 on November 30, 2000 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides.

Field of Use
The Licensee plans to develop and commercialize therapeutic methods related to the induction of angiogenesis or wound healing by administration of Fibroblast Growth Factor (FGF); and, the Licensor plans to develop and commercialize recombinant DNA methods for producing peptides/proteins.

Field shall encompass any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions. CARDIO-developed devices and methods of use thereof for delivery of angiogenic or wound healing compositions are not included within the Field, and are not subject to joint ownership or any other terms of this Agreement.

IPSCIO Record ID: 362432

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patent Rights and Licensed Technology and Licensors interest in any Improvements, subject at all times to the restrictions and obligations under a Stanford Agreement with respect to the Stanford IP, to research, develop, test, obtain Regulatory Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products, including, without limitation, any Dimerizer included or utilized therein, in the Territory, for any and all uses within the Licensed Field during the Term, and to make, have made, use, import and export, in each case solely for research purposes, including pre-clinical IND-enabling toxicology and other pre-clinical studies, but not to conduct clinical trials with respect to or to obtain Regulatory Approval for, sell or commercialize, Licensed Products, including, without limitation, any Dimerizer included or utilized therein, for any indication other than the Primary Indications until the end of the Expansion Period and, if Licensee elects to add Additional Indications to the Licensed Field during the Expansion Period, for any indication other than the Primary Indications and the Additional Indications until the end of the Non-Cancer Expansion Period.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is the owner of or otherwise controls certain proprietary Licensed Patent Rights and Licensed Technology.

Licensors Dimerizer shall mean the compound known as xx1903, all analogs and derivatives of xx1903 and any Dimerizcr or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed Patent Rights.

xx1903 is for the treatment of GvHD as an orphan drug.

GvHD shall mean a clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patients organs and tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells.

Cell Transplantation Indication shall mean GvHD or any other acute or chronic adverse clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or in the case of a bone marrow, hematopoietic or stem cell product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product.

Licensed Products include  BPX-101 (formerly BP-GMAX-CDJ) , and, CaspaCIDe Donor Lymphocyte Infusion.

Field of Use
Licensed Field shall mean the treatment or prevention of the progression or occurrence in humans of any Primary Indication and/ or any Additional Indication, such as kidney cancer, or any noncancer indication, as the case may be.

Licensee is developing cell therapies to treat cancers and other chronic and life-threatening diseases.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.